We successfully constructed and recovered a recombinant form of ALV-A strain GD13-1. This study firstly reported that ALV subgroups J, A or B all triggered ERK2 activation in primary CEF cells. PD98059 markedly suppressed ALV replication which may represent novel drug targets for preventive strategies.